For instance, in vivo studies have noted that the inhibition of IGF-1/IGF-2 sensitized pancreatic tumors to gemcitabine [93], whereas combined IGF-1R and CSF-1R inhibition significantly improved survival outcomes in mice with glioblastoma multiforme [154]. Here, IGF2 is linked to pancreatic neoplasm.